Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

11%

1 trials in Phase 3/4

Results Transparency

0%

0 of 8 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
8(88.9%)
Phase 3
1(11.1%)
9Total
Phase 1(8)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials
NCT06918587Phase 1Completed

A Comparative Evaluation of Pharmacokinetics and Immunogenicity.

Role: lead

NCT06929052Phase 1Completed

A Comparative Pharmacokinetic Study of ADL-018 Autoinjector Compared to A Pre-filled Syringe in Healthy Subjects.

Role: lead

NCT07416955Phase 1Completed

Pharmacokinetic, Immunogenicity, and Safety Evaluation of Pegfilgrastim TPI-120 in Healthy Adults

Role: lead

NCT06995482Phase 1Recruiting

Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KSHN001034 in Healthy Postmenopausal Female Volunteers

Role: lead

NCT06929039Phase 1Completed

Open Label , Randomized, Three Arm Parallel Group Single Dose Comparative Pharmacokinetic , Safety and Immunogenicity Study in Healthy Subjects

Role: lead

NCT05774639Phase 3Completed

Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria

Role: lead

NCT05564611Phase 1Completed

PK, PD, Safety & Immunogenicity of ADL-018 Lyo in Healthy Adult Subjects

Role: lead

NCT06074757Phase 1Completed

Open Label, Sequential Dosing , Single Ascending Dose and Multiple Dose Safety Tolerability and Pharmacokinetic Study

Role: lead

NCT05413161Phase 1Completed

To Compare the PK, PD, Safety & Immunogenicity of ADL-018 in Healthy Subjects

Role: lead

All 9 trials loaded